The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes.
The kinetics of activation of tumoricidal functions in mouse macrophages incubated with macrophage-activating factors (MAF) released by mitogen-stimulated lymphocytes (free MAF) and MAF encapsulated with liposomes (liposome-MAF) have been compared. Development of tumoricidal activity requires incubation of macrophages with free or liposome-encapsulated MAF for a minimum of 4 hr. Macrophages incubated with MAF for 4 hr were not cytotoxic when tumor target cells were added immediately after removal of MAF, but they were highly cytotoxic when allowed to complete a "lag" phase before being exposed to tumor cells. The duration of the lag phase varied with different activation protocols. The levels of cytotoxic activity induced by liposome-encapsulated MAF was consistently higher than that obtained with free MAF. Studies using inhibitors of endocytosis demonstrated that internalization of the liposome carrier is required for activation by liposome-MAF and that activation does not result from MAF leaking from liposomes and binding to MAF receptors on either the plasma membrane or the membrane of endocytic vesicles. Comparison of the efficiency of macrophage activation by MAF encapsulated in liposomes of differing internal volume revealed that large multilamellar and large unioligolamellar liposomes were more efficient in activating peritoneal exudate macrophages than were small unilamellar liposomes. Measurement of the volume of liposome contents internalized by macrophages from these three types of liposomes revealed that maximum cytotoxicity required internalization of a given volume of MAF-containing lymphocyte supernatants, after which no further increase in cytotoxicity occurred.
D000818:Animals; D002462:Cell Membrane / Q000502:physiology; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004705:Endocytosis; D007111:Immunity, Cellular; D007700:Kinetics; D008081:Liposomes; D008222:Lymphokines / Q000008:administration & dosage / Q000494:pharmacology*; D016215:Macrophage-Activating Factors; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D011112:Polymyxin B / Q000494:pharmacology; D011971:Receptors, Immunologic / Q000502:physiology
D008081:Liposomes; D008222:Lymphokines; D016215:Macrophage-Activating Factors; D011971:Receptors, Immunologic; D011112:Polymyxin B